Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
Etesevimab save search
Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12
Published: 2021-12-05 (Crawled : 00:00) - globenewswire.com
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: -2.2%
H: 0.0%
C: 0.0%
fda authorization bioscience merge emergency use authorization
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
Published: 2021-12-03 (Crawled : 22:00) - biospace.com/
ABCL | $3.895 -0.64% 430K
|
|
| O: 3.41%
H: 0.0%
C: 0.0%
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
covid therapy authorized antibody merge
Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12
Published: 2021-12-03 (Crawled : 20:00) - prnewswire.com
LLY | News | $749.245 -0.2% 550K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
| Email alert
Add to watchlist
covid therapy authorized antibody merge
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
Published: 2021-11-02 (Crawled : 23:00) - biospace.com/
ABCL | $3.895 -0.64% 430K
|
|
| O: -0.41%
H: 5.54%
C: 4.54%
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
covid treatment
Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
|
| O: 0.26%
H: 2.0%
C: 1.15%
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
covid treatment
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
Published: 2021-09-21 (Crawled : 19:00) - biospace.com/
ABCL | $3.895 -0.64% 430K
|
|
| O: -0.58%
H: 3.16%
C: 2.68%
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 2.04%
H: 0.72%
C: -0.81%
covid treatment
Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19
Published: 2021-09-21 (Crawled : 18:00) - prnewswire.com
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
|
| O: 0.71%
H: 0.83%
C: -0.05%
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 2.04%
H: 0.72%
C: -0.81%
covid treatment europe
Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
LLY | News | $749.245 -0.2% 550K
|
Health Technology
| Email alert
Add to watchlist
covid expansion merge authorized emergency use authorization
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19
Published: 2021-09-16 (Crawled : 22:00) - biospace.com/
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
|
| O: 0.14%
H: 0.49%
C: -0.26%
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 0.15%
H: 0.26%
C: -1.3%
covid merge authorized emergency use authorization
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
Published: 2021-09-16 (Crawled : 22:00) - biospace.com/
ABCL | $3.895 -0.64% 430K
|
|
| O: -0.11%
H: 5.8%
C: 5.38%
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 0.15%
H: 0.26%
C: -1.3%
covid fda merge authorized emergency use authorization
Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19
Published: 2021-09-15 (Crawled : 11:00) - prnewswire.com
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 0.21%
H: 2.48%
C: 0.06%
covid treatment covid-19
Distribution of Etesevimab/JS016 in the US Reopened
Published: 2021-08-29 (Crawled : 12:20) - globenewswire.com
LLY | News | $749.245 -0.2% 550K
|
Health Technology
| Email alert
Add to watchlist
distribution
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Published: 2021-04-16 (Crawled : 11:00) - prnewswire.com
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 0.79%
H: 1.56%
C: 1.0%
covid treatment merge authorized emergency use authorization
Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together
Published: 2021-04-12 (Crawled : 13:15) - biospace.com/
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.88%
covid
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
Published: 2021-03-10 (Crawled : 17:00) - biospace.com/
ABCL | $3.895 -0.64% 430K
|
|
| O: 1.27%
H: 5.99%
C: 3.83%
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 0.38%
H: 0.56%
C: -0.69%
covid phase 3 trial
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Published: 2021-03-10 (Crawled : 12:39) - biospace.com/
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 0.38%
H: 0.56%
C: -0.69%
covid phase 3 trial
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
Published: 2021-03-05 (Crawled : 00:00) - biospace.com/
ABCL | $3.895 -0.64% 430K
|
|
| O: 1.53%
H: 4.02%
C: -6.23%
covid ema
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
Published: 2021-03-05 (Crawled : 17:12) - prnewswire.com
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 0.24%
H: 3.31%
C: 2.94%
covid treatment ema
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
Published: 2021-02-26 (Crawled : 18:00) - globenewswire.com
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 1.41%
H: 0.14%
C: -0.88%
therapy antibody
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
Published: 2021-02-10 (Crawled : 08:00) - globenewswire.com
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda merge authorized covid-19 emergency use authorization
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
INVO | $1.36 78.95% 3.6M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
SWVL | $9.64 27.35% 200K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.